Mar 2022 Archives - Page 2 of 2 - ASCVD & Lipidology Knowledge Hub

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Confirm
  • Share

  • Stay up to date
  • Home
  • Topics
    • Cardiovascular Diseases and Conditions
      • Acute Coronary Syndrome
      • Atherosclerosis
      • Coronary artery disease
      • CVD
      • ASCVD
      • Myocardial Infarction
    • Lipid Metabolism and Disorders
      • Lipids
        • PUFA
          • Eicosanoids
      • Cholesterol
        • High-density lipoprotein
        • Low-density lipoprotein
        • Low-density Lipoprotein Cholesterol
        • Lipoprotein (a)
        • Apolipoprotein B
        • Hypercholesterolemia
        • Hyperlipidemia
        • Dyslipidemia
        • Familial hypercholesterolemia
      • Triglycerides
      • Cholesterol synthesis
      • Cholesterol absorption
    • Medications and Therapies
      • Therapy
      • Lipid lowering therapy
        • Statin
          • High-intensity statin
        • PCSK9
          • Alirocumab
          • Evolocumab
        • Bempedoic acid
        • Icosapent Ethyl
        • Inclisiran
        • Obicetrapib
        • Zerlasiran
      • Combination therapy
      • Aspirin
      • Immunotherapy
      • Short interfering RNA (siRNA)
      • Diabetes
    • Risk Factors and Prevention
      • CVD Risk Factor
      • Primary prevention
      • Prevention
      • Risk assessment
      • Women
      • Inflammation
      • Calcium Scoring
    • Clinical Research and Guidelines
      • Clinical Trial
      • Trials
      • Guidelines
      • Consensus statement
      • Registry
      • GOULD
    • Other Related Topics
      • Congresses
      • Global health
      • Vaccination
        • Influenza
      • Non-adherence
      • Pediatric Population
      • Plaques
      • Obesity
    • Molecular and Genetic Factors
      • ANGPTL3
  • Webinars/Videos
  • Infographics
  • Articles
  • Case Studies
  • Forum
  • Faculty
  • Unblocked
  • Stay up to date

Mar 2022 Articles

  • Articles

    Lipoprotein(a) Serum Levels Predict Pulse Wave Velocity in Subjects in Primary Prevention for Cardiovascular Disease with Large Apo(a) Isoforms: Data from the Brisighella Heart Study

    Cicero AFG, Fogacci F, Derosa G, et al.

    Journal: 

    Biomedicines

    First published: March 11, 2022  DOI: 10.3390/biomedicines10030656

    View
    • Share

  • Articles

    Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH

    Anagnostis P, Rizos CV, Skoumas I, et al.

    Journal: 

    Endocrine

    First published: March 9, 2022  DOI: 10.1007/s12020-022-03013-y

    View
    • Share

  • Articles

    How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?

    Catapano AL, Daccord M

    Journal: 

    Atherosclerosis

    First published: March 7, 2022  DOI: 10.1016/j.atherosclerosis.2022.02.013

    View
    • Share

  • Articles

    Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk

    Mehta A, Vasquez N, Ayers CR, et al.

    Journal: 

    J Am Coll Cardiol

    First published: March 1, 2022  DOI: 10.1016/j.jacc.2021.11.058

    View
    • Share

  • Articles

    Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review

    Stone NJ, Smith SC Jr, Orringer CE, et al.

    Journal: 

    J Am Coll Cardiol

    First published: March 1, 2022  DOI: 10.1016/j.jacc.2021.12.016

    View
    • Share

1 2

How would you rate this content?

  • © John Wiley & Sons, Ltd. All rights reserved.
  • Privacy Policy
  • Terms of use
  • Stay up to date
  • Cookie Preferences
  • This Knowledge Hub is supported by Novartis.
Clinical Cardiology